Transdel Pharmaceuticals Reports Excellent Results of Initial Testing on Anti-Cellulite Product Conducted by JH Direct
LA JOLLA, Calif., Sept. 9 /PRNewswire/ -- Transdel
Pharmaceuticals, Inc. (OTC:TDLP) (BULLETIN BOARD: TDLP) ("Transdel")
reported today that JH Direct has completed their initial product
testing of Transdel's anti-cellulite formulation in 24 subjects,
which consisted of observing the before and after results of
applying the product over a 16 week period. The excellent results
observed during this test have led JH Direct to initiate plans for
a final test in approximately 25 subjects to be conducted by a
third-party skin research center that will conduct a similar test
to the initial test as well as obtain additional measurements over
a 12 week period. JH Direct is planning a commercial launch of the
product for the fourth quarter of 2010 or in early 2011 subject to
successful completion of this final test.
Under the terms of its exclusive worldwide licensing agreement,
JH Direct will pay Transdel initial royalty advances and a
continuing licensing royalty on the worldwide sales of the
anti-cellulite product. The product will be initially launched
through a direct response television campaign created and managed
by JH Direct, followed by a planned expansion into traditional
channels of distribution, such as retail and wholesale
channels.
"We are pleased with JH Direct's product development progress
and commercialization plans for our anti-cellulite product; given
their significant experience and past success with direct response
television campaigns we are confident they will maximize the
potential of our product," stated John Lomoro, Acting Chief
Executive Officer and Chief Financial Officer. "The eventual launch
of this product will be a significant milestone for
Transdel."
"We are very pleased with the results that the participants
experienced from our initial testing and are excited to be moving
into the final testing phase for the anti-cellulite product,"
stated Johann Verheem, JH Direct's Chief Executive Officer. "We
believe there is a large market opportunity for an anti-cellulite
product that works as well as this product has proven in our
initial testing and we are looking forward to introducing this
product to the market."
About Transdel Pharmaceuticals, Inc.
Transdel Pharmaceuticals, Inc. (OTC:TDLP) (BULLETIN BOARD: TDLP) is a specialty
pharmaceutical company developing non-invasive, topically delivered
products. The Company's innovative-patented Transdel(TM) cream
formulation technology is designed to facilitate the effective
penetration of a variety of products through the tough skin
barrier. Ketotransdel®, the Company's lead pain product, has
completed a Phase 3 clinical trial and utilizes the Transdel(TM)
technology to deliver the active drug, ketoprofen, a non-steroidal
anti-inflammatory drug through the skin directly into the
underlying tissues where the drug exerts its well-known
anti-inflammatory and analgesic effects. The Company intends to
leverage its Transdel(TM) platform technology to expand and create
a portfolio of topical products for a variety of indications. The
Company is actively pursuing partnerships with companies to expand
its product portfolio for pharmaceutical and cosmetic/cosmeceutical
products. For more information, please visit http://www.transdelpharma.com/.
About JH Direct, LLC
JH Direct, LLC is a fully integrated Direct Response Television
Company focusing on developing sustainable brands launched through
direct response television campaigns as part of a multi-channel
distribution approach. The JH Direct senior management team has
created and managed some of the most successful Direct Response
Television brands in the cosmeceutical, beauty and fitness
categories since the mid nineties.
JH Direct is funded by JH Partners, a San Francisco-based
private equity firm focused on building sustainable, long-term
equity value in consumer and marketing-driven growth companies.
www.jhpartners.com
Safe Harbor Statement
The Company cautions you that the statements included in this
press release that are not a description of historical facts are
forward-looking statements. These include statements regarding: the
Company's interpretation of the results of the initial testing of
its anti-cellulite product; the results of the final tests of its
anti-cellulite product and JH Direct's plans to commercially launch
the anti-cellulite product. Actual results may differ materially
from those set forth in this press release due to the risks and
uncertainties inherent in the Company's business, including,
without limitation: the outcome of the final tests on the Company's
anti-cellulite product may not be favorable, the timing of JH
Direct's commercial launch of the anti-cellulite product may be
delayed, JH Direct's efforts to commercially launch the
anti-cellulite product may not be successful, the Company may
receive limited licensing proceeds, and the Company may be unable
to secure sufficient funding to complete its product development
plans. More detailed information about the Company and the risk
factors that may affect the realization of forward-looking
statements is set forth in the Company's filings with the
Securities and Exchange Commission, including its Annual Report on
Form 10-K and its Quarterly Reports on Form 10-Q filed with the
SEC. Such documents may be read free of charge on the SEC's web
site at www.sec.gov. You are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the
date hereof. All forward-looking statements are qualified in their
entirety by this cautionary statement and the Company undertakes no
obligation to revise or update this press release to reflect events
or circumstances after the date hereof. This caution is made under
the safe harbor provisions of Section 21E of the Private Securities
Litigation Reform Act of 1995.
Source: Transdel Pharmaceuticals, Inc.
CONTACT: John Lomoro, Acting Chief Executive Officer and Chief
Financial
Officer of Transdel Pharmaceuticals, Inc., +1-858-457-5300,
johnl@transdelpharma.com; or
Mark Orozco, VP of Business Development of JH
Direct, LLC, +1-760-598-1520, Mark@jhdirect.net
Web Site: http://www.transdelpharma.com/
http://www.jhpartners.com/
Posted: September 2010
